Stocktoria
GeneDx Holdings Corp. WGS
GeneDx Holdings Corp. (WGS) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $427.5M at a -4.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.3 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.304 |
| Retained earnings / assets | -2.623 |
| EBIT / assets | -0.025 |
| Equity / liabilities | 1.43 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| WGS | GeneDx Holdings Corp. | 6/9 | -5.22 | — | +40% |
| DCGO | DocGo Inc. | 4/9 | -4.05 | — | -47.7% |
| OMDA | Omada Health, Inc. | 6/9 | 2.28 | — | +53.2% |
| TALK | Talkspace, Inc. | 6/9 | 5.28 | 112.2 | +22% |
| SRTA | Strata Critical Medical, Inc. | 4/9 | 6.54 | 11.1 | +34.3% |
| USPH | U S PHYSICAL THERAPY INC /NV | 6/9 | 2.26 | 25.5 | +16.3% |
| VSEE | VSEE HEALTH, INC. | 3/9 | -16.83 | — | +40.3% |
About GeneDx Holdings Corp.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
FAQ
Is WGS financially healthy?
GeneDx Holdings Corp.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does WGS pay a dividend?
No, GeneDx Holdings Corp. does not currently pay a dividend.
How profitable is WGS?
In FY2025, GeneDx Holdings Corp. had a net margin of -4.9% and a return on equity of -6.8%.
What is the analyst price target for WGS?
The average Wall-Street price target for GeneDx Holdings Corp. is $78.44, about 4.8% below the recent price, from 9 analysts (consensus: strong buy).
Is WGS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on GeneDx Holdings Corp.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.